CNBC's Silvia Amaro takes a look at the rise and fall in Novo Nordisk shares.

Eli Lilly launched the pre-filled injector pen of its blockbuster weight-loss drug Mounjaro for 14,000 rupees (nearly $160) ...

Novo Nordisk has plummeted back to Earth after a stunning rise driven by Ozempic and Wegovy. Can the storied Danish pharma ...

Enthusiasm for its weight loss medications is intensifying, and several companies are preparing oral formulations.

Novo Nordisk (($DE:NOVA)) announced an update on their ongoing clinical study. Study Overview: Novo Nordisk recently completed a clinical study ...

The obesity market still only has two clear leaders with approved GLP-1 medications, and frontrunners Eli Lilly and Novo ...

This article covers key health news including Primary Health Properties securing a takeover bid for Assura, Novo Nordisk's ...

KBP Biosciences Pte. Ltd. (the "Company") today issued a statement addressing a further decision by the Singapore ...

Eli Lilly and Company faces valuation pressure after disappointing Orforglipron results. Discover why now isn't the time to ...

If Novo Nordisk A/S’s wildly popular weight-loss drug succeeds in a highly anticipated trial for Alzheimer’s disease, Biogen Inc.’s Chief Executive Officer Chris Viehbacher doesn’t see it as a ...

A new study connects PFA or forever chemical exposure to incident type 2 diabetes risk. Experts explain the findings and how ...

The partnership means that Apple's fitness and wellness service will be made available to all members who enrol onto ...